Mary Caffrey

If the full FDA accepts the panel's narrow recommendation, the type 2 diabetes therapy could enjoy a preferred status above its rivals in the SGLT2 market.

Two hospitals, one in Georgia and another in California, charge in lawsuits that BCBS of Georgia sends payment directly to patients instead of paying the hospitals for care provided. The patients often do not know they are supposed to sign the checks over to cover the cost of their care, and the hospitals end up without payment.

The Endocrine Society notes that diabetes has become more prevalent as people report sleeping fewer hours per night.

How does a state with almost no money launch Medicaid expansion? Louisiana health officials used data they already had, and in doing so have created a model that could be used elsewhere.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center. This session was sponsored by Janssen Pharmaceuticals.

The lawsuit seeks an additional 7 years' protection for the popular cholesterol drug, which sold 20.3 million prescriptions last year.

The keynote address from Patient-Centered Diabetes Care, presented by The American Journal of Managed Care and Joslin Diabetes Center in Teaneck, N.J., April 8, 2016.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

For African Americans in poor Mississippi counties, having diabetes and kidney disease in combination lead to cardiovascular death rates that were on par with underdeveloped nations.

This week's takedown shows that the fraud prevention and enforcement efforts that began nearly a decade ago are bearing fruit, including the change to predictive modeling to spot suspicious billing in Medicare.

An appellate panel found that a group of hospitals could not have information that Horizon withheld during discovery in 2 breach of contract suits related to its OMNIA tiered health plan. An attorney for 1 group of those hospitals said it will appeal because consumers and providers need to know how the tiered health network was created.

The study comes as regulators put increased emphasis on long-term cardiovascular outcomes trials to ensure safety of diabetes and obesity therapies. The American Journal of Managed Care recently convened an expert panel on the topic.

House Speaker Paul Ryan said the policy outline represents the first consensus among his conference to replace "Obamacare," which the document says has not worked because it has limited choice, increased consumer costs, and created new regulatory burdens for employers.

Groups seeking grants under the new program must show how they can train small practices without charging the doctors or their practices.

Using an algorithm to recommend insulin dosing, both in and out of the hospital, was shown to improve glycemic control and aid population health management.

The partnership will allow Medtronic to scale Canary Health's diabetes prevention programs to reach a wider audience and bring Canary's self-management platform into customer support for its devices.

An executive summary of the report on the PAN Foundation roundtable, presented with The American Journal of Managed Care, discussed the shift from the problem of the "uninsured" to the "underinsured."

The diabetes advocacy community has long sought Medicare coverage for continuous glucose monitoring (CGM) systems, but the technology has been deemed "precautionary." Abstracts presented at last week's ADA Scientific Sessions could help build a case for updating FDA's clearance to use CGM for dosing, removing a hurdle to Medicare coverage.

Reseachers are studying whether drugs that have been approved for treating type 2 diabetes can be used in combination with insulin to avoid both variablity in blood glucose and weight gain.

A packed session greeted the highly anticipated results of the LEADER trial, which found that the GLP-1 receptor agonist liraglutide has cardiovascular benefits in high-risk patients with diabetes.

Data from CDC consistently show that low-income, minority groups are at higher risk for diabetes, for genetic but especially for environmental reasons.

Evidence presented Sunday at the 76th Scientific Sessions of the American Diabetes Association comes as competition is heating up over a pair of therapies that combine insulin with a GLP-1 receptor agonist.

Intarcia Therapeutics anticipates filing for FDA approval at the end of the third quarter of 2016. At this year's ADA presentation, Julio Rosenstock, MD, said the insertion method for the novel therapy delivery device continues to improve.

In an ADA session called "Follow the Money," panelists led by Joslin Diabetes Center's Robert A. Gabbay, MD, PhD, FACP, discussed the diabetes cost burden, insulin costs, and payment models.

A poster at an ADA session on barriers and facilitators to novel care found that top concerns of patients with diabetes often have nothing to do with the disease. Other studies looked at which comorbidities contribute the most to readmissions or length of stay, and how an intervention that focused on transitions of care reduced A1C in patients with uncontrolled diabetes.